Besides using 89Zr-bevacizumab as PET tracer for noninvasive in vivo imaging of VEGF expression in the tumor microenvironment, potentially it can also be used to predict or monitor an antiangiogenic response. This evidence concerns the gene VEGFA and neoplasm.